Grab2Go AS continued to develop and bring its autonomous pharmacy and retail technology to market in the first half of 2026. No further material business developments occurred during the reporting period, and the previously reported project positions remain unchanged.
The regulatory framework for self-service pharmacies in Estonia remains under discussion. The outcome and timing of this process continue to affect the broader deployment of the company's solutions. Grab2Go continues to cooperate with Accelerate Estonia on agreeing the technical requirements for wider use of the technology and round-the-clock access to medicines.
The company continues to develop its value proposition for pharmaceutical retail, taking account of differences between national markets. Europe remains the primary focus of sales activities, which are directed mainly towards potential clients in the pharmaceutical retail sector.
Product development remains focused on the software and hardware platform and on meeting market needs and regulatory requirements. Operating costs remain at the minimum level needed to maintain the company's operations and the continuity of essential development activities.
Management considers regulatory clarity and additional capital to be essential for broader commercialization and future growth. The company continues to work towards creating the conditions needed to implement its strategic development plans.
Despite continuing regulatory uncertainty, management remains confident in the growth potential of autonomous pharmacy solutions. Grab2Go continues to build on its technological capabilities and the experience gained from its pilot projects to support the further development and introduction of its solutions.
Additional information can be found in the attached report.